Efficacy of botulinum toxin type A in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study
Cruse B
Published in BMJ Neurology Open
Methodology
Double-blind, randomized, placebo-controlled crossover trial with polysomnography-confirmed sleep bruxism; outcomes included masticatory muscle EMG activity, pain scores and adverse events after targeted BTX-A injection.
Key Findings
Targeted botulinum toxin type A injection into masseter and temporalis muscles reduced sleep bruxism episode intensity and self-reported bruxism-related pain versus placebo, with no serious adverse events.
Conclusions
Targeted BTX-A injection is a safe and effective treatment for SB.
Limitations
Small sample (n=22), short follow-up per period, specialised injection technique limiting generalisability, and effects are symptomatic rather than curative.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.